Rechercher | AC Mingle

NutrWellnessHub Ajouter une nouvelle offre d'emploi Art
2026-08-29 09:17:58 -

LumiMeds GLP1: Understanding Tirzepatide and GLP-1 Care
Introduction LumiMeds GLP1 is an web-based weight loss service that is medically supervised through the LumiMeds platform. The programme may include compounded semaglutide, compounded tirzepatide, or another medication chosen by a licensed healthcare provider, per the patient’s medical history and eligibility. These treatments are prescription medications, not...

0 Commentaires 0 Parts 110 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
atharv2711 Ajouter une nouvelle offre d'emploi Autre
2026-09-21 10:16:30 -

Tirzepatide API Market Size to Reach USD 8.80 Billion by 2034 at 17.9% CAGR | Market Share, Growth, Forecast & Outlook
According to a report by Intel Market Research, the global Tirzepatide API Market was valued at USD 1.86 billion in 2025, estimated at USD 2.35 billion in 2026, and projected to reach USD 8.80 billion by 2034, representing a 17.9% CAGR during 2026–2034. The market covers pharmaceutical-grade tirzepatide active pharmaceutical ingredient used in regulated finished-dose manufacturing, while...

0 Commentaires 0 Parts 24 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!
Rutujad Ajouter une nouvelle offre d'emploi Autre
2026-09-22 09:19:54 -

GLP-1 Agonists Weight Loss Drugs Market Demand for Convenient Treatment Options
The weight management industry is moving through a major shift as pharmaceutical treatments become an increasingly visible part of obesity care. GLP-1-based medicines have moved from being primarily associated with metabolic disease management to becoming a major category within weight loss treatment, supported by rising obesity prevalence, clinical efficacy, greater awareness, and expanding...

0 Commentaires 0 Parts 10 Vue 0 Aperçu

Connectez-vous pour aimer, partager et commenter!